A Double-Blind, Randomized, Repeat Dose, Parallel Group Study of Recombinant Human Parathyroid Hormone (rhPTH(1-31)NH2) tablets, or Placebo tablets, Compared to Open Label Forteo in Postmenopausal Women with Osteoporosis

Registry ID

EUCTR2010-020342-98

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Unigene Laboratories, Inc.

Start date

2011-02-11

Completion date

2011-10-21

Last update

2026-08-16

Conditions

• Postmenopausal Osteoporosis

Summary

To characterize percent change from baseline in bone mineral density (BMD) at L1-L4 axial lumbar spine after 24 weeks of once daily treatment of 5 mg tablets of rhPTH(1 31)NH2.

Locations

• , , Estonia
• , , Lithuania
• , , Denmark

Related clinical trials

• Blackcurrants Modify Gut Microbiota and Reduce Osteoporosis Risk in Postmenopausal Females
• Can Serum Lumican Level Identify a Hidden Fragility Phenotype Beyond Bone Mineral Density in Postmenopausal Women?
• StrAtegies For Zoledronic Acid Post-dEnosumab Discontinuation in Postmenopausal oSTeoporosis
• A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study to Evaluate the Safety, Tolerability and Efficacy of AGA2118 in Postmenopausal Women with Low Bone Mineral Density

View on source registry